AstraZeneca and Absci use AI to create cancer drugs
Pharmaceutical company AstraZeneca has signed a deal worth nearly $247 million with Absci, an artificial intelligence company, to develop antibodies to fight cancer, Reuters reports. Absci’s collaboration with AstraZeneca is aimed at creating a generative AI model with a minimum level of risk for the development of new advanced antibodies. So far, the companies have […]